FDA advisory panel calls for suicide warnings over new antidepressants

Ray Moynihan*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

9 Citations (Scopus)


n a surprise move on 2 February, a panel of scientific advisers of the US Food and Drug Administration urged the agency to warn that new anti-depressants may increase the risk of suicidal thinking or behaviour among children and teenagers.

During a 10 hour hearing, experts weighed the official presentations of uncertain scientific data against powerful emotional testimony from dozens of families whose children have killed themselves or others after taking a selective serotonin reuptake inhibitor—a class including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil, Seroxat).
Original languageEnglish
Pages (from-to)303-303
Number of pages1
JournalBMJ (Clinical research ed.)
Issue number7435
Publication statusPublished - 5 Feb 2004


Dive into the research topics of 'FDA advisory panel calls for suicide warnings over new antidepressants'. Together they form a unique fingerprint.

Cite this